Inactive Instrument

Pluristem Therapeutics Share Price Nasdaq

Equities

Biotechnology & Medical Research

Sales 2022 234K 18.45M Sales 2023 287K 22.63M Capitalization 32.98M 2.6B
Net income 2022 -41M -3.23B Net income 2023 -28M -2.21B EV / Sales 2022 58 x
Net cash position 2022 26.21M 2.07B Net cash position 2023 10.27M 809M EV / Sales 2023 79.1 x
P/E ratio 2022
-0.96 x
P/E ratio 2023
-1.04 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 76.12%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 52 31/10/06
Director of Finance/CFO 40 30/04/13
Chairman 70 25/09/05
Members of the board TitleAgeSince
Director/Board Member 73 14/07/21
Director/Board Member 55 10/07/23
Chairman 70 25/09/05
More insiders
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
Calendar
More about the company